Shares of Biogen Inc. BIIB advanced 5.65% to $120.49 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 9.52% to 5,456.90 and ...

Shares of Biogen Inc. BIIB slipped 4.31% to $114.05 Tuesday, on what proved to be an all-around poor trading session for the ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) has been given a consensus rating of “Hold” by the thirty-one brokerages that are ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Morgan Stanley lowered the firm’s price target on Biogen (BIIB) to $152 from $157 and keeps an Equal Weight rating on the shares. The firm ...

Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline. Read why SAGE ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 27.8 ...

Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

Manufacturers of Alzheimer’s disease drugs have identified blood tests as a way to accelerate diagnosis and treatment.

Regeneron Pharmaceuticals Inc REGN raises some concerns due to its significant presence in Ireland. If tariffs are applied, they would likely increase the cost of goods sold since companies often ...